CordenPharma’s Latest Initiatives: Advancements in Peptides and Reentry into the Oligo Market
An exclusive interview
CDMO CordenPharma is making significant strides in the peptide space. According to Brian McCudden, President and CEO of CordenPharma Colorado, the company operates three peptide API manufacturing sites located in Brussels, Frankfurt, and Colorado, specializing in various aspects of peptide synthesis, development, and manufacturing.
“We have a lot of exciting new offerings in the peptide space,” McCudden said, during an interview at TIDES USA 2023 in San Diego, Calif.
The Brussels site focuses on both liquid-phase and solid-phase peptide synthesis, while the Frankfurt location is in the process of expanding its operations to include early-phase clinical GMP manufacturing. The Colorado operation is engaged in peptide development and GMP manufacturing at different scales.
“The Colorado site is expanding significantly its peptide manufacturing, especially in the mid-scale, and also adding a lot of infrastructure to support even further peptide manufacturing capabilities,” McCudden said.
In addition to its advancements in the peptide space, CordenPharma is reentering the oligonucleotide market, the company announced in May. The company’s goal is to provide an integrated offering that meets the complex needs of its clients, according to McCudden.
For example, “we’re going to be tying the oligonucleotide into the LMP formulation, lipid manufacturing and sterile injectable fill and finish at our Caponago, Italy, plant,” he said.
Previously, the company had paused oligonucleotide manufacturing to concentrate on peptide manufacturing but is now focused on enhancing the company’s previous offerings, according to McCudden. Backed by its new owner, Astorg, a European private equity firm, CordenPharma plans to introduce a multiphase offering that includes process and analytical development and mid-scale manufacturing in phases one and two, and further evaluation for phase three to address unmet client needs.
McCudden said CordenPharma differentiates itself as a TIDES CDMO by offering innovative solutions in both development and manufacturing.
“We can offer these at every scale out there from small scale, mid-scale, and large scale in the US and Europe,” he said.
